All Peptides
Tirzepatide

Tirzepatide

Dual GIP/GLP-1 agonist for enhanced fat loss

$449/mo

Virtual consult + lab work required

This peptide requires a brief virtual visit and recent bloodwork before our team can prescribe.

Details

Virtual Consult

Our licensed provider reviews your health profile via secure video — typically 10 minutes. Required for any peptide prescription.

Required Labs

  • Comprehensive Metabolic Panel (CMP)
  • Lipid Panel
  • HbA1c
  • Thyroid Panel (TSH, Free T3, Free T4)

Refund Policy: If found not eligible due to health reasons after consultation, you will receive a full refund.

Product Details

About Tirzepatide

Mechanism of Action

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike single-mechanism therapies, it simultaneously activates both GIP and GLP-1 receptors, creating a synergistic effect that produces superior weight loss outcomes. The GIP component enhances insulin secretion and may reduce food intake, while the GLP-1 component regulates appetite, slows gastric emptying, and improves glycemic control.

Scientific Background

The dual agonist approach leverages the complementary actions of two incretin hormones. GIP receptors are expressed in adipose tissue, bone, and pancreatic beta cells, while GLP-1 receptors are found in the pancreas, brain, heart, and gastrointestinal tract. Research suggests that GIP may enhance the weight loss effects of GLP-1 agonism by promoting energy expenditure and reducing inflammation in adipose tissue. The balanced activation of both pathways appears to maximize therapeutic benefits while potentially reducing side effects compared to GLP-1 monotherapy.

Clinical Applications

FDA-approved for type 2 diabetes and chronic weight management, tirzepatide has demonstrated the highest weight loss efficacy among approved obesity medications. SURMOUNT clinical trials showed average weight loss of 15-22% depending on the dose, surpassing results seen with GLP-1 agonists alone. Beyond weight reduction, patients experience improvements in lipid profiles, liver function markers, blood pressure, and inflammatory markers. The medication represents a significant advancement in treating metabolic syndrome and obesity-related complications.

Evidence-Based

Clinical Research & Studies

Backed by peer-reviewed research from leading medical journals

2022
Peer Reviewed

SURMOUNT-1: Tirzepatide for weight reduction in obesity

Tirzepatide produced dose-dependent weight loss, with participants losing an average of 15.0% (5mg), 19.5% (10mg), and 20.9% (15mg) of their body weight over 72 weeks, significantly exceeding placebo (3.1%).

Read Full Study
2023
Peer Reviewed

SURMOUNT-2: Tirzepatide in obesity with type 2 diabetes

In patients with obesity and type 2 diabetes, tirzepatide achieved mean weight reductions of 12.8% (10mg) and 14.7% (15mg) with significant improvements in HbA1c and cardiometabolic risk factors.

Read Full Study
2023
Peer Reviewed

Dual GIP and GLP-1 receptor agonism: mechanisms and clinical potential

Review of the synergistic mechanisms underlying dual incretin therapy, highlighting superior metabolic outcomes and the potential for addressing multiple aspects of metabolic syndrome simultaneously.

Read Full Study
Explore More

Related Resources

Similar Peptide Therapies

Semaglutide
$349/mo

Semaglutide

GLP-1 receptor agonist for significant weight loss

Learn More
Retatrutide
$549/mo

Retatrutide

Triple-action metabolic optimization

Learn More

Educational Articles

Article

Understanding GLP-1 Agonists: The Science Behind Weight Loss

Read Article
Article

Semaglutide vs Tirzepatide: Which is Right for You?

Read Article
Article

The Future of Weight Loss: Dual and Triple Agonist Peptides

Read Article